Cargando…

Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis

BACKGROUND: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Miraldi Utz, Virginia, Bulas, Sabrina, Lopper, Sarah, Fenchel, Matthew, Sa, Ting, Mehta, Mitul, Ash, Daniel, Lovell, Daniel J., Kaufman, Adam H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884783/
https://www.ncbi.nlm.nih.gov/pubmed/31783768
http://dx.doi.org/10.1186/s12969-019-0383-9
_version_ 1783474617264898048
author Miraldi Utz, Virginia
Bulas, Sabrina
Lopper, Sarah
Fenchel, Matthew
Sa, Ting
Mehta, Mitul
Ash, Daniel
Lovell, Daniel J.
Kaufman, Adam H.
author_facet Miraldi Utz, Virginia
Bulas, Sabrina
Lopper, Sarah
Fenchel, Matthew
Sa, Ting
Mehta, Mitul
Ash, Daniel
Lovell, Daniel J.
Kaufman, Adam H.
author_sort Miraldi Utz, Virginia
collection PubMed
description BACKGROUND: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were evaluated. METHODS: Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or follow-up examination frequency. RESULTS: Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention. Mean age at IFX initiation was 10.4 ± 4.5 years; initial mean dose was 6.6 ± 2.2 mg/kg [and given at weeks 0, 2, 4 and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9–128] months. Prior to IFX, 14/27 patients had failed adalimumab ± methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye [OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed 10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence. CONCLUSIONS: This study adds significantly to the IFX literature by documenting outstanding uveitis control with long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of treatment adherence on uveitis control.
format Online
Article
Text
id pubmed-6884783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68847832019-12-03 Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis Miraldi Utz, Virginia Bulas, Sabrina Lopper, Sarah Fenchel, Matthew Sa, Ting Mehta, Mitul Ash, Daniel Lovell, Daniel J. Kaufman, Adam H. Pediatr Rheumatol Online J Research Article BACKGROUND: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were evaluated. METHODS: Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or follow-up examination frequency. RESULTS: Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention. Mean age at IFX initiation was 10.4 ± 4.5 years; initial mean dose was 6.6 ± 2.2 mg/kg [and given at weeks 0, 2, 4 and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9–128] months. Prior to IFX, 14/27 patients had failed adalimumab ± methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye [OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed 10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence. CONCLUSIONS: This study adds significantly to the IFX literature by documenting outstanding uveitis control with long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of treatment adherence on uveitis control. BioMed Central 2019-11-29 /pmc/articles/PMC6884783/ /pubmed/31783768 http://dx.doi.org/10.1186/s12969-019-0383-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Miraldi Utz, Virginia
Bulas, Sabrina
Lopper, Sarah
Fenchel, Matthew
Sa, Ting
Mehta, Mitul
Ash, Daniel
Lovell, Daniel J.
Kaufman, Adam H.
Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title_full Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title_fullStr Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title_full_unstemmed Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title_short Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
title_sort effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884783/
https://www.ncbi.nlm.nih.gov/pubmed/31783768
http://dx.doi.org/10.1186/s12969-019-0383-9
work_keys_str_mv AT miraldiutzvirginia effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT bulassabrina effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT loppersarah effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT fenchelmatthew effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT sating effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT mehtamitul effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT ashdaniel effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT lovelldanielj effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis
AT kaufmanadamh effectivenessoflongterminfliximabuseandimpactoftreatmentadherenceondiseasecontrolinrefractorynoninfectiouspediatricuveitis